Skip to main content
MSF.org
MSF Staff
  • English
  • العربية
  • Español
  • Français
.هذه الصفحة غير متاحة باللغة العربية
Esta página no está disponible en este idioma.
Cette page n’est pas disponible dans cette langue.
This page is not available in this language.
MSF medical guidelines
MSF medical guidelines

Main navigation

  • Home
  • Guidelines
  • Internal guidelines
  • Updates
  • Order
  • About
  • Favorites
  • Contact

All guidelines

Tuberculosis

Essential drugs

English العربية Spanish French

Clinical guidelines - Diagnosis and treatment manual

English العربية Spanish French

Essential obstetric and newborn care

English العربية French

Management of A CHOLERA EPIDEMIC

English French

Management of A MEASLES EPIDEMIC

English French

Tuberculosis

English French

Public health engineering

English French
  • Authors/Contributors
  • Introduction
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnosis and follow-up investigations
  • Chapter 4: Diagnosis of active tuberculosis in children
  • Chapter 5: Diagnostic algorithms for pulmonary tuberculosis (PTB) in adults and adolescents
  • Chapter 6: Screening for active tuberculosis
  • Chapter 7: Case definitions for registration
  • Chapter 8: Tuberculosis drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant and rifampicin-resistant tuberculosis
  • Chapter 11: Treatment of rifampicin-susceptible and isoniazid-resistant tuberculosis
  • Chapter 12: Tuberculosis and HIV co-infection
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Infection prevention and control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices
    • Appendix 1. Xpert assays
    • Appendix 2. Interpretation of Xpert assay results
    • Appendix 3. Collection, storage, and shipment of respiratory specimens
    • Appendix 4. Sputum smear microscopy
    • Appendix 5. Time required for diagnostic test results
    • Appendix 6. Ventilated workstation and biosafety cabinet
    • Appendix 7. Lymph node fine needle aspiration
    • Appendix 8. Protein estimation
    • Appendix 9. Tuberculin skin test
    • Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis
    • Appendix 11. Use of TB drugs in pregnant or breastfeeding women
    • Appendix 12. Dose adjustments in renal insufficiency
    • Appendix 13. Daily dose of TB drugs using fixed-dose combinations
    • Appendix 14. Monitoring of patients on drug-susceptible TB treatment
    • Appendix 15. Monitoring of patients on drug-resistant TB treatment
    • Appendix 16. Additional investigations in drug-resistant TB
    • Appendix 17. Management of adverse effects
      • Gastrointestinal disorders
      • Neurotoxicity
      • Endocrine disorders
      • Dermatological disorders
      • Musculoskeletal disorders
      • Miscellaneous
    • Appendix 18. Compassionate use of TB drugs
    • Appendix 19. Drug interactions and overlapping toxicities
    • Appendix 20. Treatment supporters
    • Appendix 21. Therapeutic patient education
    • Appendix 22. Assessment of adherence to TB treatment
    • Appendix 23. Basic tool for assessing risk of TB transmission
    • Appendix 23. Treatment card for patients on first-line anti-TB therapy
    • Appendix 24. Recommendations for air change per hour
    • Appendix 24. Tuberculosis register for patients on first-line anti-TB therapy
    • Appendix 25. Overview of ventilation techniques
    • Appendix 25. Treatment card for patients on second-line anti-TB therapy
    • Appendix 26. Germicidal ultraviolet lamps
    • Appendix 26. Tuberculosis register for patients on second-line anti-TB therapy
    • Appendix 27. Respirators
    • Appendix 28. Surgical masks
    • Appendix 29. BCG vaccine
    • Appendix 29. Sputum smear microscopy register
    • Appendix 30. Xpert MTB/RIF register
    • Appendix 32. Quaterly report
    • Appendix 33. Report on detection and enrolment of TB cases with rifampicin and multidrug-resistance
    • Appendix 34. Request form for smear microscopy and Xpert assays
    • Appendix 34. Report of final outcomes of drug-resistant tuberculosis
    • Appendix 35. Request form for culture, pDST, LPA, genome sequencing
    • Appendix 35. Check-list for the evaluation of a TB service
    • Appendix 36. Drug-o-gram

Breadcrumb

  • Home
  • Tuberculosis
  • Appendices

Appendix 17. Management of adverse effects

Select language:
Enter
Permalink
Download
Comment
Return to top
On this page

     

    Update: January 2022

     

    • Gastrointestinal disorders
      • Abdominal pain
      • Diarrhoea
      • Epigastric pain
      • Hepatotoxicity
      • Metallic taste
      • Nausea and vomiting
    • Neurotoxicity
      • Depression
      • Headache
      • Optic neuritis
      • Ototoxicity
      • Peripheral neuropathy
      • Psychosis
      • Seizures
    • Endocrine disorders
      • Gynecomastia
      • Hypothyroidism
    • Dermatological disorders
      • Alopecia
      • Fungal infection
      • Photosensitivity
      • Skin reactions
    • Musculoskeletal disorders
      • Arthralgias
      • Tendinitis/tendon rupture
    • Miscellaneous
      • Electrolyte disorders
      • Haematologic disorders
      • Lactic acidosis
      • Nephrotoxicity
      • QT prolongation

     

     

    Path

    Book traversal links for Appendix 17. Management of adverse effects

    • Appendix 16. Additional investigations in drug-resistant TB
    • Gastrointestinal disorders

    Send feedback about this page or ask a general question

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    MSF medical guidelines
    MSF medical guidelines
    © Médecins Sans Frontières 2023

    Footer

    • Disclaimer
    • Cookie Policy
    • Privacy Notice